NewsRegistration of iPS cell stock (QHJI strain) for clinical use as a U.S. Drug Master File
The CiRA Foundation ("CiRA_F") is pleased to announce that two cell lines from the HLA homozygous iPS cell stock for clinical use have been registered as a Drug Master File ("DMF") of the U.S. Food and Drug Administration ("FDA").
Background
CiRA_F manufactures iPS cells for clinical use from the blood of healthy donors and provides them to research institutions and companies at a reasonable price.
We have registered our iPS cell stock as a DMF to facilitate companies that are conducting research and development on regenerative medicine using our iPS cell stock to apply for approval in the U.S.
Registered iPS cell lines
We have registered 2 of our 27 lines from our HLA homozygous iPS cell stock (ID: QHJI01s04 and QHJI14s04). These iPS cell lines were manufactured from the blood of a donor with the most frequent HLA type in Japan (donor ID: QHJI). Currently, more than 10 projects by other institutions are transplanting cells produced from these cells into patients and conducting clinical trials to confirm their safety and efficacy.
Contents of this DMF
What is the Drug Master File System
Companies developing regenerative medical products using our iPS cell stock must submit detailed information about the stock when submitting applications to the FDA. Registering the cell lines as a DMF will simplify these procedures.
CiRA_F will continue to contribute to the development of regenerative medicine using iPS cells by strengthening cooperation with research institutions and companies.
Funders
Inquiries
The CiRA Foundation
Public Relations Group, Planning Department
E-mail:contact*cira-foundation.or.jp
(please change the * to @)